Drugs / THE-630
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05160168 | Jan 2022 → Feb 2024 | connective and soft tissue neoplasm, connective tissue neoplasm, gastrointestinal stromal tumor | Theseus Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | THE-630 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05160168 ↗ |
| Action | Inhibit | “KIT tyrosine kinase inhibitor” NCT05160168 ↗ |
| Route | Oral | “orally administered THE-630” NCT05160168 ↗ |
| Target | KIT | “KIT tyrosine kinase inhibitor” NCT05160168 ↗ |